{"product_id":"global-hemato-oncology-testing-market-size-study-forecast-by-product-services-assay-kits-services-cancer-leukemia-acute-lymphoblastic-acute-myeloid-non-hodgkin-s-lymphoma-technology-pcr-ngs-ihc-end-user-clinical-laboratories-hospita","title":"Global Hemato Oncology Testing Market Size study \u0026 Forecast, by Product \u0026 Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospita","description":"\u003cp\u003eGlobal Hemato Oncology Testing Market Size study \u0026amp; Forecast, by Product \u0026amp; Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Hemato Oncology Testing Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Hemato Oncology Testing is the diagnosis, treatment, and prevention of blood diseases, while oncology is the treatment of cancer. Hematology-oncology encompasses hemophilia, iron deficiency anaemia, leukemias and lymphomas, sickle cell disease, thalassemia’s, and other organ cancers. The Hemato Oncology Testing market is expanding because of factors such as the rising incidences of hematologic cancer and increasing demand for personalized therapy.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the PMC PubMed Central in 2018, around 174,250 people across the United States in 2018 were diagnosed with homological malignancies.  Also, the incidences are rising about 1.29 million people are living with HM’s. According to the American Society of Clinical Oncology in 2020, the estimated number of cancers is higher in females with around 712,758 than in males with 679,412 in 2020. Whereas advanced molecular techniques for hemato-oncology diagnostics and increasing drug-diagnostic co-development create lucrative opportunities for the market. However, unfavorable reimbursement scenario hampers the market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Hemato Oncology Testing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing prevalence of hematologic cancer, growing aging population, and awareness of advanced treatment methods. Whereas, North America is expected to grow significantly during the forecast period, owing to factors such as growing prevalence of leukemia, lymphoma, and multiple myeloma diseases, growing R\u0026amp;D activities by market players in the forecast period\u003c\/p\u003e\n\n\u003cp\u003eMajor market players included in this report are:\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nAbbott\u003cbr\u003e\nInvitae Corporation (Archerdx, Inc)\u003cbr\u003e\nQIAGEN\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nIllumina Inc.\u003cbr\u003e\nBio-Rad Laboratories, Inc.-\u003cbr\u003e\nMolecularmd (Subsidiary of Icon PLC)\u003cbr\u003e\nAsuragen, Inc.\u003cbr\u003e\nArup Laboratories Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In May 2018, Adaptive Biotechnologies (US) and Sanofi, SA. (US) collaborated to use Adaptive's clonoSEQ Assay to assess MRD status in response to isatuximab.\u003cbr\u003e\n? In July 2018, Abbott Laboratories (US) received FDA approval for its Abbott RealTime IDH1 kit\u003cbr\u003e\nGlobal Hemato Oncology Testing Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Product \u0026amp; Service, Cancer Type, Technology, End User, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003cbr\u003e\nThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Product \u0026amp; Service:\u003cbr\u003e\nAssay Kits\u003cbr\u003e\nServices\u003c\/p\u003e\n\n\u003cp\u003eBy Cancer:\u003cbr\u003e\nLeukemia\u003cbr\u003e\nNon-Hodgkin’s Lymphoma\u003c\/p\u003e\n\n\u003cp\u003eBy Technology:\u003cbr\u003e\nPCR, Polymerase chain reaction\u003cbr\u003e\nNGS, Next-generation sequencing (NGS)\u003cbr\u003e\nIHC Immunohistochemistry (IHC)\u003c\/p\u003e\n\n\n\u003cp\u003eBy End-User:\u003cbr\u003e\nClinical Laboratories,\u003cbr\u003e\nHospitals\u003c\/p\u003e\n\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eF. Hoffmann-La Roche Ltd\u003cbr\u003e\nAbbott\u003cbr\u003e\nInvitae Corporation (Archerdx, Inc)\u003cbr\u003e\nQIAGEN\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nIllumina Inc.\u003cbr\u003e\nBio-Rad Laboratories, Inc.-\u003cbr\u003e\nMolecularmd (Subsidiary of Icon PLC)\u003cbr\u003e\nAsuragen, Inc.\u003cbr\u003e\nArup Laboratories Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 200 Pages \/ MCW16226943","offer_id":47640175542578,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-hemato-oncology-testing-market-size-study-forecast-by-product-services-assay-kits-services-cancer-leukemia-acute-lymphoblastic-acute-myeloid-non-hodgkin-s-lymphoma-technology-pcr-ngs-ihc-end-user-clinical-laboratories-hospita","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}